QDEL1 Stock Chart & Stats
$570.28
$0.00(0.00%)
At close: 4:00 PM EDT
$570.28
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$238.74 - $570.28
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
$17.07B
Enterprise Value$3.89B
Total Cash (Recent Filing)$123.40M
Total Debt (Recent Filing)$3.08B
Price to Earnings (P/E)―
Beta-0.17
Next Earnings
Nov 03, 2026EPS Estimate
3.79Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-15.44
Shares Outstanding68,575,424
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)1.03
Price to Sales (P/S)0.73
P/FCF Ratio-23.93
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$226.59Price Target Upside-60.27% Downside
Rating ConsensusHold
Number of Analyst Covering2
EPS Forecast (FY)14.44
Revenue Forecast (FY)$47.62B
Bulls Say, Bears Say
Bulls Say
Ex-China Revenue GrowthBroad growth across core laboratory, immunohematology, and point-of-care franchises outside China indicates resilient underlying demand and a diversified commercial base. Continued expansion across multiple regions can support recurring consumables utilization and reduce dependence on any single market over the next several quarters.
Adjusted EBITDA ExpansionStrong adjusted EBITDA growth and margin expansion show that cost control and operating discipline are improving profitability despite a seasonally weak quarter. If maintained, better earnings conversion can strengthen investment capacity, support deleveraging, and improve the economics of the installed diagnostic platform.
Lower Historical DebtThe substantial reduction in TTM debt versus prior years represents a meaningful improvement in balance-sheet structure and financial flexibility. Lower absolute debt can reduce interest burden and refinancing exposure, giving management a stronger foundation to fund commercial initiatives and address current cash-generation pressures.
Bears Say
Persistent Profitability WeaknessDeeply negative profitability and cash generation indicate that the current business is not yet funding itself reliably from operations. Sustained losses can constrain investment, increase reliance on financing, and make the company more vulnerable if revenue growth or margin improvement does not continue over the next several quarters.
China Pricing UncertaintyThe proposed pricing changes are affecting customer purchasing behavior and inventory levels, creating a structural uncertainty for QuidelOrtho's China business rather than a single-quarter fluctuation. Broader product scope and additional pilot provinces could prolong pressure on revenue, mix, and regional profitability.
Leverage And Covenant ConstraintsThe amended financing framework preserves covenant relief but also imposes tighter requirements over time and limits several capital-allocation actions. These constraints can reduce strategic flexibility while management works to improve cash conversion, particularly given the company's reported need to prioritize leverage reduction.
QuidelOrtho News
QDEL1 FAQ
What was QuidelOrtho’s price range in the past 12 months?
QuidelOrtho lowest stock price was $238.74 and its highest was $570.28 in the past 12 months.
What is QuidelOrtho’s market cap?
QuidelOrtho’s market cap is $17.07B.
When is QuidelOrtho’s upcoming earnings report date?
QuidelOrtho’s upcoming earnings report date is Nov 03, 2026 which is in 3 days.
How were QuidelOrtho’s earnings last quarter?
QuidelOrtho released its earnings results on Aug 06, 2026. The company reported $2.442 earnings per share for the quarter, beating the consensus estimate of -$0.921 by $3.363.
Is QuidelOrtho overvalued?
According to Wall Street analysts QuidelOrtho’s price is currently Overvalued.
Does QuidelOrtho pay dividends?
QuidelOrtho does not currently pay dividends.
What is QuidelOrtho’s EPS estimate?
QuidelOrtho’s EPS estimate is 3.79.
How many shares outstanding does QuidelOrtho have?
QuidelOrtho has 68,575,424 shares outstanding.
What happened to QuidelOrtho’s price movement after its last earnings report?
QuidelOrtho reported an EPS of $2.442 in its last earnings report, beating expectations of -$0.921. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of QuidelOrtho?
Currently, no hedge funds are holding shares in MX:QDEL1
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
QuidelOrtho Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$226.59 (-60.27% Downside)
$226.59 (-60.27% Downside)
Blogger Sentiment
Neutral
MX:QDEL1 Sentiment 67%
Sector Average 64%
Sector Average 64%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-50.57%
12-Months-Change
Fundamentals
Return on Equity
-55.30%
Trailing 12-Months
Asset Growth
-10.41%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
QuidelOrtho
QuidelOrtho Corporation specializes in the creation and production of diagnostic testing solutions, addressing a wide array of healthcare testing demands. The company operates through distinct business units. Its Labs division provides clinical chemistry and immunoassay instruments and tests designed to analyze bodily fluids and proteins, aiding in health assessment, patient management, and tracking disease progression. The Transfusion Medicine unit focuses on ensuring blood safety and compatibility by offering immunohematology and infectious disease screening tests for blood and plasma. For rapid results in various clinical environments, the Point-of-Care segment delivers quick diagnostic tests. Additionally, the Molecular Diagnostics arm develops advanced polymerase chain reaction thermocyclers, analyzers, and amplification systems. QuidelOrtho distributes its offerings both directly to end-users and through an extensive network of distributors. These products are utilized by professionals in settings such as medical offices, hospitals, clinical and reference laboratories, urgent care centers, universities, retail clinics, pharmacies, wellness screening centers, and blood/donor banks, as well as for individual, non-professional, and over-the-counter applications. Founded in 1979 and based in San Diego, California, the company maintains a global footprint, including operations across North America, Europe, the Middle East, Africa, and China.
QDEL1 Company Deck
QDEL1 Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call conveyed a mixed picture: solid underlying operational performance outside China (mid-single-digit growth ex-China, strong regional results, 21% YoY adjusted EBITDA growth, and margin expansion) and tangible progress on the Lex/Neulixa commercialization. Offsetting these positives were significant near-term headwinds — a 23% revenue decline in China driven by IVD pricing uncertainty, a softer respiratory season, negative operating and free cash flow in the quarter, withdrawal of free-cash-flow guidance, and elevated leverage (4.3x). Management emphasized disciplined cost actions, cash-conversion priorities, and mitigation plans, but the combination of China uncertainty and weak respiratory demand creates meaningful short-term risk even as core franchises remain resilient.View all MX:QDEL1 earnings summariesQDEL1 Stock 12 Month Forecast
Average Price Target
$226.59
▼(-60.27% Downside)